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Abstract
Background: A primary goal of asthma management is the reduction of exacerbation risk. We assessed the
occurrence of oral corticosteroid-requiring exacerbations (OCS exacerbations) with long-term fluticasone/for-
moterol therapy, and compared it with the occurrence of similar events reported with other inhaled cortico-
steroid/long acting b2-agonist (ICS/LABA) combinations.
Methods: The occurrence of OCS exacerbations was assessed in two open-label trials of fixed-dose fluticasone/
formoterol administered for between 26 to 60 weeks in adults and adolescents with asthma. The incidence of
OCS exacerbations with fluticasone/formoterol was compared with those reported in three recent Cochrane
meta-analyses of other ICS/LABAs.
Results: The pooled incidence of OCS exacerbations with long-term fluticasone/formoterol was 2.1% (95% CI: 1.1,
3.2%, n/N¼ 16/752). In only two of the nineteen treatment arms summarized by Cochrane did OCS exacerbation
incidence approximate that seen in the two fluticasone/formoterol trials (single-inhaler fluticasone/salmeterol [2.9%];
separate inhaler budesonide, beclometasone, or flunisolide plus formoterol [3.4%]). In Lasserson’s review the pooled
incidence of OCS exacerbations for single-inhaler combinations was 9.5% (95% CI: 8.4, 10.6%; n/N¼ 239/2516) for
fluticasone/salmeterol, and 10.6% (95% CI: 9.3, 11.8%; n/N¼ 257/2433) for budesonide/formoterol. In Ducharme’s
and Chauhan’s meta-analyses (primarily incorporating separate inhaler combinations [fluticasone, budesonide, be-
clometasone, or flunisolide plus salmeterol or formoterol]), the pooled incidences of OCS exacerbations were 16.0%
(95% CI: 14.2, 17.8%, n/N¼ 258/1615) and 16.7% (95% CI: 14.9, 18.5, n/N¼ 275/1643), respectively.
Conclusions: The incidence of exacerbations in two fixed-dose fluticasone/formoterol studies was low and less
than in the majority of comparable published studies involving other ICS/LABA combinations. This difference
could not be readily explained by differences in features of the respective studies and may be related to the
favorable pharmacological/mechanistic characteristics of the constituent components fluticasone and formoterol
compared to other drugs in their respective classes.
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Introduction
The reduction of exacerbation risk is a primary goalof asthma management.(1,2) Prior exacerbations,(3,4) poor
asthma control,(4,5) activity limitation,(4) treatment compli-
ance,(6) lower forced expiratory volume in the first second
(FEV1),
(3,7–9) and allergic rhinitis(10,11) are predictors of fu-
ture exacerbation risk. Asthma exacerbations impair quality
of life, cause significant debilitation, and in rare cases may
lead to death. Exacerbations are associated with absences
from work or school and increased healthcare costs.(12–14)
Although there is no standardized definition of an asthma
exacerbation, there is agreement that asthma exacerba-
tions requiring oral corticosteroids are intuitively meaning-
ful,(1,2,15) and this simple, clinically relevant outcome has
routinely been evaluated in most asthma trials, allowing
between-trial comparisons.(15–20)
Combination inhaled corticosteroid (ICS)/long-acting b2-
agonists (LABAs) reduce the risk of exacerbations com-
pared to ICS alone(16,21,22) and are recommended where
asthma is not controlled with ICS monotherapy. A combi-
nation of fluticasone propionate (fluticasone) and formoterol
fumarate (formoterol) in an HFA pMDI inhaler (fluticasone/
formoterol; flutiform) has been evaluated in a compre-
hensive programme of randomized controlled clinical tri-
als.(23–29) In addition, the long-term tolerability and safety of
fluticasone/formoterol has been demonstrated in two open-
label, fixed-dose clinical trials of 60 weeks (Study 1)(30) and
26–52 weeks (Study 2)(31), respectively. Here we assess the
occurrence of exacerbations requiring oral corticosteroid
therapy in those two studies. To contextualize these data, we
assessed the occurrence of similar events reported with other
ICS/LABAs in three recent Cochrane meta-analyses,(22,32,33)
drawn in turn from a total of twelve long-term fixed-dose
studies in broadly similar patient populations.
Materials and Methods
The occurrence of oral corticosteroid-requiring exacer-
bations (OCS exacerbations) was assessed in Studies 1(30) and
2(31) of fluticasone/formoterol given at a fixed dose in 752
asthmatic patients aged ‡12 years. The incidence of OCS
exacerbations with fluticasone/formoterol was compared with
those reported in the three most recent Cochrane meta-
analyses detailing the efficacy and safety of other fixed dose
ICS/LABA combinations in asthma. The meta-analyses did
not include ICS/LABA studies where doses could be varied
dependent upon treatment response or those employing
‘‘SMART’’ or ‘‘MART’’ maintenance and reliever strategies.
Factors known to predict or modify asthma exacerbation
risk, based on consistent evidence from the published litera-
ture, were examined with the relevant data from each trial
extracted and checked by two authors (SD and BG). Where
the requisite data was not available from at least a third of the
Cochrane studies (e.g., baseline eosinophil levels) the corre-
sponding data were not summarized, given the difficulty in
drawing any meaningful conclusions thereof.
Long-term fluticasone/formoterol studies
Both fluticasone/formoterol studies were of an open-label,
long-term, multicentre design and enrolled two distinct
populations of patients.
Study 1(30) (a follow-on study) assessed the long-term
safety and efficacy of fluticasone/formoterol 250/10 lg
twice daily (b.i.d.) over 60 weeks in 280 patients who had
completed an earlier 12-week phase 3 trial(34) within the
previous 24 weeks. Patients had 40%–80% predicted FEV1,
and were using £500lg fluticasone or equivalent/day [Study
1: NCT00747318/EudraCT 2008-002460-34; preceding 12-
week trial: NCT00649025/EudraCT 2007-005653-37].
Key exclusion criteria for the parent study were: a history
of life-threatening asthma, hospitalization or intubation for
asthma within the past year, an emergency room (ER) visit
for asthma or OCS for asthma in the preceding 3 months, the
use of omalizumab within 6 months or leukotriene receptor
antagonists within 1 week, and a smoking history within the
preceding 12 months. Asthma medications other than study
treatment were prohibited during the study and patients were
discontinued if they required systemic corticosteroid treat-
ment for an asthma exacerbation.
In the parent study, patients received fluticasone/for-
moterol 250/10 lg b.i.d. (N = 146) or fluticasone 250 lg
b.i.d. (N = 292); 392 patients (89.5%) completed and 46
patients discontinued, of these, 4 patients (1 fluticasone/
formoterol, 3 fluticasone) discontinued due to asthma ex-
acerbations, and 16 (1 fluticasone/formoterol and 15 fluti-
casone) due to loss of asthma control. A total of 280 patients
continued into the follow-on study (i.e. Study 1).
Study 2(31) evaluated the long-term safety of fluticasone/
formoterol 100/10 lg or 250/10 lg b.i.d. in 472 patients with
40%–85% predicted FEV1 and using £500lg/day flutica-
sone or equivalent (allocation to fluticasone/formoterol dose
group was dependent upon the patient’s pre-study ICS
dose). Key exclusion criteria and prohibited concomitant
medications were very similar to Study 1; however, in Study
2 patients could only enter the study with uncontrolled
asthma and concomitant antimuscarinics were not specifi-
cally precluded. As in Study 1, the use of systemic corti-
costeroids for worsening asthma led to discontinuation from
the study. The first 80 patients in each dose group received
treatment for 12 months. Subsequent patients were treated
for 6 months (NCT00394121/EudraCT 2005-003518-14).
For the main analysis, patients in Studies 1 and 2 were
considered to have an ‘‘OCS exacerbation’’ if they had an
asthma exacerbation that was treated with an oral, intra-
muscular, or intravenous corticosteroid for asthma: this al-
lowed a like-for-like comparison with OCS exacerbation
frequency as reported in the three Cochrane meta-analyses.
A second definition of ‘‘respiratory exacerbations’’ was
employed as a sensitivity analysis: patients were deemed to
have a respiratory exacerbation if they received an oral,
intramuscular, or intravenous corticosteroid for any respi-
ratory illness. This definition was primarily intended to
identify potentially miscoded OCS exacerbations. Patients
captured by either definition who required hospital man-
agement were identified.
Compliance with ethics
Study 1 and Study 2 were conducted in accordance with
the Declaration of Helsinki and International Conference on
Harmonisation Good Clinical Practice guidelines, and were
approved by the relevant independent ethics committees. All
patients provided written informed consent.
FLUTICASONE/FORMOTEROL: LOW RATE OF EXACERBATIONS 347
Other ICS and LABA combination therapies
Data on the incidence of OCS exacerbations with other
combinations of an ICS and LABA were obtained from
three recent Cochrane reviews (Ducharme et al.;(22) Las-
serson et al.;(32) Chauhan and Ducharme(33)), selected as
they were the most recent, relevant meta-analyses of fixed
dose ICS/LABA combination therapy in asthma that in-
cluded specific analyses of OCS exacerbations. From the
Cochrane reviews we focused only on studies of patients
aged ‡12 years and only on studies of >16 weeks to ensure
comparability with the fluticasone/formoterol studies. The
primary outcome measure in all three Cochrane meta-
analyses was the number of patients with one or more
exacerbations requiring oral steroids (i.e., the incidence of
OCS exacerbations).
The meta-analysis by Lasserson et al.(32) estimated the
relative effects of fixed-dose single-inhaler fluticasone/
salmeterol and budesonide/formoterol in five head-to-head
long-term studies. OCS exacerbations were reported in
four of the five studies (Aalbers et al.,(35) Busse et al.,(36)
COMPASS [Kuna et al.],(37) EXCEL [Dahl et al.](38)). The
four studies included 4949 patients, and each compared
regular maintenance treatment with budesonide/formoterol
400/12 lg b.i.d. with fluticasone/salmeterol 250/50 lg/day
(Table 1). Notably, the Lasserson studies were of somewhat
shorter duration (24 or 28 weeks) than the fluticasone/
formoterol studies (26/52 weeks or 60 weeks).
The meta-analysis by Ducharme et al.(22) compared fixed
dose ICS plus LABA versus the same fixed dose of ICS
alone in patients with asthma insufficiently controlled on
ICS monotherapy. Five long-term studies (duration 24 to 52
weeks) from this Cochrane review (Pauwels et al. [FA-
CET],(16) O’Byrne et al. [OPTIMA],(18) Aubier et al.,(39)
Fitzgerald et al.,(40) and van der Molen et al.(41)) including
1615 patients, reported OCS exacerbations and are pre-
sented here. The studies all involved separate inhaler ICS/
LABA combinations (fluticasone + salmeterol, budesonide +
formoterol, beclometasone + formoterol, and flunisolide +
formoterol); Aubier et al. also evaluated a single-inhaler
ICS/LABA (fluticasone/salmeterol) (Table 1). O’Byrne
et al.(18) and Pauwels et al.(16) both evaluated two dose
levels in their respective studies.
Chauhan and Ducharme’s meta-analysis(33) compared the
addition of a LABA versus that of a leukotriene receptor
agonist to the treatment regimen of asthmatics who re-
mained symptomatic despite regular ICS. There were three
long-term studies summarized in this review (Bjermer
et al.,(42) Ilowite et al.,(43) and Price et al.(44)), including
1655 patients overall, which reported OCS exacerbations.
The studies by Bjermer et al.(42) and Ilowite et al.(43) used
separate inhaler ICS/LABA combinations (fluticasone +
salmeterol), whilst the study by Price et al.(44) allowed a
range of separate or single inhaler ICS/LABA combinations
(beclometasone, budesonide or fluticasone + salmeterol or
formoterol or budesonide/formoterol or fluticasone/salme-
terol) (Table 1).
Key entry criteria for the studies described above are
summarized in Table 2 and were broadly comparable with
patients’ requirement for step-up to ICS/LABA ascertained
in all but one case (FACET). Only the COMPASS study
specifically recruited patients with a history of recent ex-
acerbations (‡ 1 in the previous 1–12 months). All other
studies excluded patients with a recent history of exacer-
bations, although the exact criteria varied from study to
study. Studies 1 and 2 and the EXCEL study excluded pa-
tients with exacerbations in the preceding 3 months, while
Aalbers et al., Busse et al., COMPASS, van der Molen et al.,
Bjermer et al., and Ilowite et al. all excluded patients with
exacerbations within 1 month of study entry.
In the FACET study only very frequent exacerbators (3 or
more courses of OCS or hospitalization due to asthma in the
6 months before study entry) were excluded. Patients in the
study by Price et al., were excluded if they were experi-
encing an acute asthma exacerbation or had used systemic
corticosteroids within 2 weeks of study entry. Fitzgerald
et al. excluded patients who had had an exacerbation re-
quiring an emergency room visit within 3 months of study
entry. The studies reported by Aubier et al. and the OPTI-
MA study did not specify any inclusion/exclusion criteria
regarding prior asthma exacerbations or recent systemic
corticosteroid use.
There was some variation in baseline ICS doses: the two
fluticasone/formoterol studies, the COMPASS study, and
those of Aalbers et al. and Busse et al. imposed an upper
limit for enrolment of 500–600 lg fluticasone propionate-
equivalents (FP-e)/day. In the OPTIMA study, patients were
ICS-naive or on a low dose of £200 lg FP-e/day. Somewhat
higher screening doses of up to 800 to 1000 lg FP-e/day
were permitted in the remaining studies (Table 2).
Patients in most studies had uncontrolled symptoms at
baseline, defined as the use of rescue medication and/or the
presence of asthma symptoms during the run-in period
(Table 2). The exceptions were fluticasone/formoterol Study
1, which mandated uncontrolled symptoms at the start of the
previous 12-week double-blind study, but not at the start of
the 60 week extension study, and the FACET study, which
required that randomized patients had stable asthma.
Following enrollment, only two of the studies mandated
treatment with oral steroids for specific exacerbation crite-
ria: the FACET study in case of a >30% decrease from
baseline peak expiratory flow rate (PEFR) for 2 consecutive
days (as well as if deemed necessary by the investigator for
clinical need) and van der Molen et al., where PEFR de-
creased by >20% from baseline for 2 consecutive days.
Studies 1 and 2 were conducted across different territories
(Study 1; Central, South and North America and Eastern
Europe: Study 2; Eastern and Western Europe). Of the
Cochrane studies, eight were performed in Europe and/or
North America (one study also included Israel), whilst the
countries in which four studies were undertaken were not
specified (Table 1).
Data analysis
The incidence of OCS exacerbations (main analysis) and
respiratory exacerbations (sensitivity analysis) for the fluti-
casone/formoterol studies was calculated by dividing the
number of patients with at least one exacerbation event by
the total number of patients in the studies, and the 95%
confidence interval (CI) was calculated. A similar approach
was used to calculate the pooled incidence of OCS exac-
erbations for fixed-dose fluticasone/salmeterol and budeso-
nide/salmeterol for the studies included from Lasserson
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et al., and for the ICS and LABA combinations included
from Ducharme et al. and Chauhan and Ducharme.
Results
Baseline characteristics of patients
Patient characteristics in the 12 Cochrane studies were
broadly similar to those in the fluticasone/formoterol studies
(Table 3). The mean age was 42–43 years in Studies 1 and 2,
and 36–50 years for those from the Cochrane analyses.
Mean FEV1 % predicted was 67%–73% in Studies 1 and 2,
and similar in 10 out of the 12 Cochrane studies (68%–
79%), but somewhat higher in the study by Aalbers et al.
and the OPTIMA study (84%–87%). Limited ethnicity data
were available but, where detailed, patients were predomi-
nantly white. Whereas in the fluticasone/formoterol studies
very few black patients (0.4%–2.1%) were enrolled, as in
studies by Bjermer et al. and Price et al., higher proportions
were enrolled in two studies performed solely at U.S. cen-
ters (Busse et al., Ilowite et al.) (Table 3).
Treatment adherence
In both fluticasone/formoterol studies, adherence (as-
sessed via patient diary cards and dose counter review) was
high: 98% and 95% of subjects in Study 1 and 2, respec-
tively, took at least 70% of their medication. Adherence data
were available for 5 of the 11 Cochrane-summarized stud-
ies.(35–37,39,44) High levels of adherence were seen in 4 of
these studies: mean treatment compliance was ‡94% in
Aubier’s and Aalbers’ studies, whilst ‡93% of subjects in
Busse et al. and COMPASS reported taking at least 80% of
their study medication. By contrast, in Price et al.’s real
Table 3. Baseline Characteristics of Patients by Study
Study
Mean
age
Gender
(% male:female) Ethnicity
FEV1
% predicted Reversibility (%)
FP/FORM studies
1 43 35:65 White 74.6%
Black 2.1%
Asian 0.4%
Hispanic 19.6%
Other 3.2%
67 NR
2 42 46:54 White 98.9%
Black 0.4%
Asian 0.6%
73 28
Lasserson et al (32) Cochrane review of single inhaler FP/SAL versus single inhaler BUD/FORM
Aalbers, 2004 (35) BUD/FORM
FP/SAL
46 45:55 NR 84 NR
46 49:51 NR 85 NR
Busse, 2008 (36) BUD/FORM
FP/SAL
39 34:66 White 82.0%
Black 13.8%
Other 4.2%
79 NR
39 43:57 White 84.0%
Black 12.3%
Other 3.7%
78 NR
COMPASS (37) BUD/FORM
(Kuna, 2007) FP/SAL
38 41:59 NR 73 25
38 43:57 NR 73 23
EXCEL(38) BUD/FORM
(Dahl, 2006) FP/SAL
47 41:59 NR 79 24
46 44:56 NR 79 20
Ducharme et al (22) Cochrane review of ICS/LABA free combinations
Aubier, 1999 (39) Single inhaler
Separate inhalers
46 57:43 NR 73 16
48 50:50 NR 73 18
Fitzgerald, 1999 (40) 36 53:47 NR 79 NR
OPTIMA (18) Low dose ICS
(O’Byrne, 2001) High dose ICS
37 45:55 NR 86 NR
37 41:59 NR 87 NR
FACET (16) Low dose ICS
(Pauwels, 1997) High dose ICS
41 50:50 NR 76 NR
42 47:53 NR 76 NR
van der Molen, 1997 (41) 41 49:51 NR 68 25
Chauhan, Ducharme (33) Cochrane review of addition to ICS of LABAs versus anti-leukotrienes
Bjermer, 2003 (42) 41 45:55 White 77.4%
Black 0.5%
Asian 7.4%
Other 14.7%
73 19
Ilowite, 2004 (43) 38 37:63 White 85.6%
Black 7.7%
Hispanic 5.1%
74 19
Price, 2011 (44) 50 39:61 White 98%
Other 2%
NR NR
BUD, budesonide; FORM, formoterol; FP, fluticasone propionate; ICS, inhaled corticosteroid; NR, not reported; SAL, salmeterol.
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world study, adherence (based on prescriptions issued) with
LABA was only 46% and with ICS only 64%.
Incidence of exacerbations with fluticasone/formoterol
Fluticasone/formoterol was associated with a similar, low
incidence of OCS exacerbations in both studies (Fig. 1 and
Table 4). The OCS exacerbation rate was 1.8% (95% CI:
0.2, 3.3%, n/N = 5/280) in Study 1 and 2.3% (95% CI: 1.0,
3.7%, n/N = 11/472) in Study 2. The pooled incidence of
OCS exacerbations with long-term fluticasone/formoterol
therapy was 2.1% (95% CI: 1.1, 3.2%, n/N = 16/752).
The incidence of respiratory exacerbations (sensitivity
analysis, including patients who received corticosteroids for
any respiratory illness) was slightly higher: 2.9% of patients in
Study 1 (95% CI: 9.1, 4.8%, n/N= 8/280) and 3.0% of patients
in Study 2 (95% CI: 1.4, 4.5%, n/N= 14/472). The pooled
respiratory exacerbation rate was 2.9% (95% CI: 1.7, 4.1%,
FIG. 1. OCS exacerbation incidences for individual studies of ICS/LABA combinations. ICS/LABA OCS
exacerbation rates are for studies 1 and 2, and in the individual studies as reported in the Cochrane meta-
analyses by Lasserson et al.(32) Ducharme et al.,(22) and Chauhan and Ducharme.(33) BDP, beclometasone;
BUD, budesonide; FLN, flunisolide; FORM, formoterol; FP, fluticasone propionate; SAL, salmeterol.
Table 4. Long-Term Pooled OCS Exacerbation Rates with ICS/LABA Combinations*
ICS/LABA combination
OCS exacerbation rate
n / N % 95% confidence interval
Fluticasone/formoterola 16 / 752 2.1 1.1, 3.2
Fluticasone/formoterolb 22 / 752 2.9 1.7, 4.1
Fluticasone/salmeterol [Lasserson, 2011 (32)] 239 / 2516 9.5 8.4, 10.6
Budesonide/formoterol [Lasserson, 2011 (32)] 257 / 2433 10.6 9.3, 11.8
ICS/LABA combinations [Ducharme, 2010 (22)] 258 / 1615 16.0 14.2, 17.8
ICS/LABA combinations [Chauhan, 2014 (33)] 275 / 1643 16.7 14.9, 18.5
*Derived from fluticasone/formoterol studies and meta-analyses by Lasserson et al., 2011, Ducharme et al., 2010, and Chauhan and
Ducharme, 2014.
OCS exacerbation, oral corticosteroid-requiring exacerbation.
aPooled OCS exacerbation rate from Studies 1 and 2 (main analysis includes patients with an exacerbation treated with an oral,
intramuscular, or intravenous corticosteroid); bPooled severe exacerbation rate from Studies 1 and 2 (sensitivity analysis includes patients
treated with oral, intramuscular, or intravenous corticosteroid for any respiratory illness).
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n/N= 22/752), and the pooled hospitalization rate due to OCS
exacerbations was 0.1% (95% CI: 0, 0.4%, n/N= 1/752).
Incidence of exacerbations with
other ICS/LABA combinations
The pooled incidence of OCS exacerbations from the four
studies reported by Lasserson et al. was higher than that
observed for fluticasone/formoterol at 9.5% (95% CI: 8.4,
10.6%; n/N = 239/2516) for single-inhaler fluticasone/sal-
meterol (250/50 lg b.i.d.), and 10.6% (95% CI: 9.3, 11.8%;
n/N = 257/2433) for single-inhaler budesonide/formoterol
(400/12 lg b.i.d.) (Table 4). Variation in the incidence of
OCS exacerbations was relatively low, ranging from 9.1%
to 13.7% for budesonide/formoterol, and from 8.8% to
15.3% for fluticasone/salmeterol (Fig. 1).
For the ICS and LABA combinations in the five studies
from Ducharme et al., the pooled incidence of OCS exacer-
bations was also notably higher than that seen with flutica-
sone/formoterol at 16.0% (95% CI: 14.2, 17.8%, n/N= 258/
1615, Table 4). Across the five studies, the incidence of OCS
exacerbations varied considerably (range: 2.9% to 29.5%)
and was greater than 10% in four of five studies (Fig. 1). Two
studies (OPTIMA and FACET) assessed two dose levels of
budesonide in conjunction with formoterol; in both studies,
fewer OCS exacerbations were seen in the high dose group
than in the low dose group (12.4% vs. 18.0% and 19.1% vs.
29.5%, respectively). OCS exacerbations resulting in hospi-
talization were reported for ICS/LABA combinations in the
Aubier et al., FACET, and van der Molen et al. studies, with
an average hospitalization rate of 0.5% (n/N= 4/888).
The pooled incidence of OCS exacerbations for the ICS
and LABA combinations in the three studies from Chauhan
and Ducharme’s Cochrane review(33) was very similar to
that from the Ducharme et al.,(22) at 16.7% (95% CI: 14.9,
18.5, n/N = 275/1643, Table 4). OCS exacerbation rates were
more than 2-fold higher in the study by Price et al. (36.3%,
Fig. 1) compared with the studies by Bjermer et al. (14.4%)
and Ilowite et al. (14.2%). Exacerbations resulting in hos-
pitalization were reported for 0.7% of patients (n/N = 5/718)
receiving fluticasone + salmeterol free combination in the
Ilowite et al. study. Hospitalization rates were not reported
by Bjermer et al. or Price et al.
Discussion
Long-term fixed dose fluticasone/formoterol therapy was
associated with a low incidence of OCS exacerbations in
two separate studies: The pooled incidence of exacerba-
tions in 752 patients was only 2.1% (95% CIs 1.1%, 3.2%)
following a mean of 10 months treatment. A sensitivity
analysis of ‘‘respiratory’’ exacerbations, which included
any respiratory events treated with a systemic corticoste-
roid including those not reported as asthma exacerbations,
produced similar results (pooled incidence 2.9% [95% CIs
1.7%, 4.1%]).
The difference in OCS exacerbation incidence between
the fluticasone/formoterol studies versus those reviewed by
the Cochrane collaboration was surprising; a low incidence
of exacerbations similar to that noted in the two fluticasone/
formoterol studies was only reported by Aubier et al.(39) (for
one of two arms in that study, single inhaler fluticasone/
salmeterol) and by Fitzgerald et al.(40) (formoterol added to
budesonide, beclometasone or flunisolide) from amongst 19
available datasets (Fig. 1). To better understand why such
cross-trial differences might have been observed, we as-
sessed key aspects of all studies with the potential to in-
fluence the occurrence of exacerbations.
Only one ‘‘real world’’ study was included amongst all
those we reviewed, that of Price and co-workers.(44) Inclu-
sion criteria were less restrictive than in the other studies
assessed, with no requirement for patients to exhibit bron-
chodilator reversibility criterion or demonstrate correct in-
haler technique prior to enrollment, nor exclusion of patients
with significant co-morbidity or smoking history, and no
restriction on concomitant medications. This study was as-
sociated with a considerably higher incidence of exacerba-
tions on ICS/LABA treatment (36.3%) compared to all other
studies we reviewed. This clearly suggests that the observed
difference in exacerbation incidence is largely due to pa-
tient selection and the minimally interventional, ‘‘real life’’
nature of the study, likely allied to a prolonged study du-
ration of 24 months and low rates of real world treatment
adherence. The data of Price et al. are therefore of limited
relevance to the fluticasone/formoterol data, hence the re-
mainder of this discussion focuses primarily on the other
11 published studies (and 18 associated treatment arms).
Prior exacerbations are the strongest independent pre-
dictor of future exacerbation risk.(4,5,45) In patients with
asthma of varying severities, an exacerbation at baseline
approximately trebles the odds of having an exacerbation at
1 year.(4,45) Most of the ICS/LABA studies we reviewed
clearly detailed enrollment criteria with respect to prior
exacerbations. Only the COMPASS study specifically re-
cruited a population with a prior history of exacerbations,
hence this design difference was not the basis for the ex-
acerbation incidence difference between the fluticasone/
formoterol and other studies reported. Interestingly, the in-
cidence of OCS exacerbations in COMPASS was very
similar to those in several of the other studies assessed.
All studies (including COMPASS) excluded patients with
‘‘recent’’ exacerbations, although studies differed in the
length of time that patients had to be exacerbation-free prior
to enrolment and in terms of the exact description of ex-
cluded exacerbations. Theoretically these differences might
have impacted on exacerbation incidence during each trial
if, for example, temporal clustering of exacerbations occurs
in asthma in a similar manner to that described in COPD(46)
(albeit this has not, to our knowledge, been described in
asthma).
However, although the fluticasone/formoterol and EX-
CEL studies shared similar (3-month) exacerbation-free
periods pre-study, the respective incidences of exacerbations
clearly differed between these two studies (2.1% [flutica-
sone/formoterol] versus 9.5% [fluticasone/salmeterol] and
10.6% [budesonide/formoterol]). Furthermore the incidence
of exacerbations in EXCEL with both fluticasone/salmeterol
and budesonide/formoterol was similar to those observed for
these single inhaler combinations in COMPASS, and the
studies of Busse et al. and Aalbers et al. (which each stip-
ulated a 1 month exacerbation-free period). Thus there was
no clear relationship between the exacerbation-free interval
and subsequent exacerbation incidence in our review.
One study in which the exacerbation exclusion criterion
employed does appear to be pertinent is FACET. Pauwels
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et al. only excluded very frequent exacerbators (3 or more
OCS exacerbations within the past 6 months) from study
participation. Note that FACET was one of only two studies
(alongside van der Molen et al.) that stipulated that OCS
should be instituted when reductions in PEFR of a certain
magnitude were observed. These two studies reported the
highest incidence of exacerbations across all those assessed
(excluding Price’s ‘‘real-world’’ study). Thus OCS treat-
ment criteria based on PEFR would appear to explain, at
least in part, the much greater exacerbation incidences in
FACET and van der Molen’s studies than in our own. In
FACET, however, OCS could also be instituted based on
clinical need, and 73% of OCS exacerbations were a result
of clinical need rather a drop in PEFR.(47) Hence, treatment
criteria alone do not explain the high exacerbation incidence
in FACET. The recruitment of all but the most frequent
exacerbators into this study therefore appears to be the most
likely cause of the high exacerbation incidence subsequently
observed.
Lung function impairment is another of the most con-
sistent, independent predictors of future exacerbation
risk.(3,4,8,9,45) For example, Osborne and colleagues(8) re-
ported a relative risk for acute care of 2.43 in asthmatics
with FEV1 60%–80% predicted compared to those with
FEV1 >80% predicted. Similar results were reported in a
Dutch asthma cohort.(9) Given these observations it is in-
teresting that mean lung function in the two fluticasone/
formoterol studies (67% and 73%, respectively) was to-
wards the lower end of the spectrum compared to the other
studies assessed. van der Molen et al. reported a mean
baseline of 68% predicted FEV1, whilst COMPASS and
Aubier’s study reported baseline values of 73% predicted
FEV1. In the other studies reviewed, mean baseline lung
function ranged from 76% to 87% predicted FEV1. Thus
the degree of lung function impairment in the fluticasone/
formoterol studies does not explain the low exacerbation
incidences subsequently seen, although it may have con-
tributed to the high exacerbation incidence noted in van der
Molen’s study (in addition to the PEFR criteria stipulating
when OCS should be instituted).
Another factor associated with the occurrence of exac-
erbations is uncontrolled disease.(4,5,45) To simplify matters,
given the use of different baseline descriptors of symp-
tomatology, we categorized studies as either mandating or
not mandating symptomatic disease as an enrollment crite-
rion. Only two studies did not mandate the enrollment of
symptomatic patients: fluticasone/formoterol Study 1 and
FACET. Given that the incidences of OCS exacerbations in
fluticasone/formoterol Studies 1 and 2 were very similar
(1.8% and 2.3%, respectively), an enrollment criterion
specifying symptomatic disease did not appear to influence
the subsequent reporting of OCS exacerbations—possibly
because the parent study to Study 1 did include a ‘‘symp-
tomatic disease’’ inclusion criterion. Furthermore it is
noteworthy that in FACET, despite the enrollment of pa-
tients with stable disease at baseline, the OCS exacerbation
incidence (19.1% and 29.5% on high and low dose bude-
sonide + formoterol, respectively) was amongst the highest
across all the studies assessed (Fig. 1). Overall, therefore,
differences in baseline symptomatology did not appear to
explain the lower incidence of exacerbations in the flutica-
sone/formoterol versus other studies.
The territories in which the studies were undertaken were
reviewed, as the management and reporting of exacerbations
may conceivably vary in different countries, resulting in
regional differences in exacerbation incidence in a manner
similar to that observed for COPD.(48) Despite similar ex-
acerbation incidences seen therein, the two fluticasone/for-
moterol studies were conducted across different territories.
Unfortunately four of the published studies we examined did
not detail the countries in which they were undertaken.
However, from the available data no clear trends could be
discerned to suggest that regional differences played a major
role in influencing the occurrence of exacerbations ob-
served.
ICS dose at study entry, a plausible surrogate for disease
severity and/or treatment response(49) was also examined.
Broadly speaking, two study groups were evident: those
where patients were on £500–600lg FP-e/day (which in-
cluded both fluticasone/formoterol studies) and those in
which £800–1000 lg FP-e/day was allowed. Although very
few studies presented the actual ICS dose at study entry, for
those which did, the highest exacerbation incidences were
seen in FACET and van der Molen’s studies, both of which
fell into the higher dose ICS category.
However, the dose entry criteria were not necessarily an
indicator of actual ICS dose levels at study entry; the mean
pre-study ICS dose in Aalbers’ study (ICS entry criterion
250–600 FP-e) was 368lg/day, whereas in FACET an ICS
entry criterion of £800lg FP-e resulted in a mean baseline
ICS dose of 419 lg/day. The high exacerbation incidences in
the FACET and van der Molen studies may therefore be
related to other aspects of their respective study designs, as
discussed above, rather than prior ICS dose as a surrogate
for disease severity.
Ethnicity was examined as exacerbations are more fre-
quent in African American asthmatics than their white
counterparts, even when concomitant medications(50) and
socioeconomic factors(51) are adjusted for. Whilst ethnicity
data were limited, it is relevant that in two Cochrane studies
(Busse et al. and Ilowite et al.) higher proportions of black
patients were enrolled (7.7%–13.8%) than in the fluticasone/
formoterol studies (0.4%–2.1%). These imbalances could
plausibly have contributed to the exacerbation incidence
differences observed. However, of all Cochrane studies,
only Busse’s and Ilowite’s were conducted at US sites alone
where proportions of black patients are likely to be higher
than in multinational or European studies. Furthermore,
even with enrollment of approximately 8%–14% black pa-
tients in Busse and Ilowite’s studies, any increase in exac-
erbation incidence in the overall population would be
expected to be modest based on the reported occurrence of
exacerbations in long-term studies of African American
asthmatics.(52–54) As such, any inflation of overall exacer-
bation incidence differences between fluticasone/formoterol
and other treatments in our review is likely to be very
limited.
Concomitant use of other anti-asthma therapies was also
reviewed, given the potential for add-on medications to
further reduce the occurrence of exacerbations. Although
use of other asthma medications was permitted by Price
et al., Fitzgerald et al., and Aubier et al., none allowed the
concomitant use of leukotriene modifiers and, whilst two
studies(39,44) permitted the use of anticholinergics, long-
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acting antimuscarinics do not appear to have been em-
ployed. Thus, there appear to be no important differences in
allowed concomitant asthma medications between any of
the trials reviewed.
Trial duration was examined as exacerbation incidence
inevitably increases with time and because a reduced fre-
quency of asthma exacerbations is seen in the summer
months.(55,56) Study 1 was of 14 months duration, and in
Study 2 approximately 46% of patients were allocated to 12
months treatment (the remainder were treated for 6 months),
ensuring exposure to annual peaks in exacerbation fre-
quency for at least two-thirds of the 752 patients. In com-
parison, of the eleven published studies (excluding Price
et al.), only OPTIMA and FACET were of 12 months du-
ration and two others (Ilowite et al. and Bjermer et al.)
approached 12 months duration (both 48 weeks). In these
four studies, exacerbation incidences ranged from 14.2% to
29.5%. The remaining seven published studies were all of
24 to 28 weeks duration. Thus, four of the six studies in
which the highest occurrences of exacerbations were re-
ported were of at least 48 weeks duration. Given that the
high event incidence in one of the shorter studies (van der
Molen et al.: 24 weeks) appears to have been driven by the
institution of OCS based on PEFR criteria, the importance
of duration to event incidence becomes even more evident.
The low event incidence in the fluticasone/formoterol
studies is perhaps surprising in view of these observations.
The devices and formulations employed were examined
given the association of the fine particle fraction (FPF) with
pulmonary drug deposition(57,58) and clinical outcomes.(59)
In most Cochrane studies where specific devices/formula-
tions were mandated, the Turbuhaler or Diskus/Accuhaler
were used to administer dry powder formulations of bude-
sonide/formoterol and fluticasone/salmeterol, respectively,
or the corresponding monoproducts in combination. The
FPFs (expressed as a percentage of nominal dose) of these
products at relevant flow rates are approximately 20%–35%
(Turbuhaler) and 15%–20% (Diskus).(60,61) By comparison,
the FPF of the fluticasone/formoterol HFA pMDI combi-
nation product is approximately 42%.(60) Thus, resulting
differences in lung dose could potentially be implicated in
the lower exacerbation occurrence seen in the fluticasone/
formoterol studies.
In the two trials(36,37) in which the budesonide/formoterol
pMDI (FPF approximately 44%)(62) and fluticasone/salme-
terol pMDI (FPF approximately 30%–35%)(62,63) were em-
ployed, both of which have higher FPFs than their respective
DPI products, no appreciable reduction in exacerbation in-
cidence versus the corresponding DPI trial data were seen.
However, other pharmaceutical factors can influence drug
delivery from pMDIs and fast forceful plumes may increase
impaction of drug in the throat thereby reducing lung de-
position, negating any benefit of a high FPF.(64)
Fluticasone/formoterol pMDI has a slower, longer lasting,
and gentler plume than that of fluticasone/salmeterol,(64)
which may plausibly be associated with in vivo differences in
lung deposition and therefore also outcomes. No published
plume data are available for budesonide/formoterol pMDI.
Hence, the pharmaceutical characteristics of fluticasone/for-
moterol pMDI may have contributed to the exacerbation
differences observed. However, given the clinical dose-
response for both ICSs(65–67) and LABAs(68) is relatively
shallow, the apparent magnitude of exacerbation risk reduc-
tion with fluticasone/formoterol remains somewhat surprising.
Finally, treatment adherence was evaluated given its as-
sociation with clinical outcomes.(69,70) Adherence in the
fluticasone/formoterol studies and the four Cochrane stud-
ies(35–37,39) (excluding Price et al.) for which data were
available was uniformly high. Of note in Price et al.’s real
world study, adherence (based on prescriptions issued) with
LABA was only 46% and with ICS only 64%. This low (but
typically ‘‘real life’’) level of adherence is likely to be an
important contributory factor to the much higher exacerba-
tion incidence seen therein.
In summary, our review of studies suggested that the real
world nature of Price et al.’s study, the institution of OCS in
response to PEFR criteria by van der Molen et al., and the
recruitment of all but the most recurrent exacerbators in
FACET are likely to have contributed significantly to the
high event occurrence subsequently seen in those studies. In
the remaining nine Cochrane-reviewed studies (including 15
treatment arms), there were no compelling design, device/
formulation, population, or adherence-related characteristics
to explain the considerably higher exacerbation incidence
(in 13 of 15 treatment arms) than in both fluticasone/for-
moterol studies. Amongst these studies, no greater concor-
dance was evident between the designs/populations of the
fluticasone/formoterol studies and Aubier’s and Fitzgerald’s
studies (in which low exacerbation incidences were seen),
compared to the other studies reviewed.
We acknowledge the limitations of attempting to extricate
and evaluate individual features of these studies from amongst
several others. A further limitation of our review is that, de-
spite all studies detailing exacerbation-related enrollment cri-
teria, none detailed the actual prior annual exacerbation rates
in the patients recruited. In addition, biomarker data, such as
fractional exhaled nitric oxide (FeNO) and blood/sputum eo-
sinophils, which have been shown to be predictive of exac-
erbation risk(71,72) and response to treatment,(73–75) were also
unavailable for review.
Despite the above limitations, the comparatively low
exacerbation incidence in both fluticasone/formoterol stud-
ies remains somewhat surprising, even in view of the
pharmaceutical characteristics of fluticasone/formoterol that
may have contributed to our results; our review of Cochrane
trials suggests an exacerbation incidence of 10%–15% to be
more in keeping with expectations—assuming that all ICSs
and LABAs have similar effects at an equipotent dose.
However, a variety of recent data suggest that this may not
be the case.
In their meta-analysis, Adams et al.(76) compared fluti-
casone versus budesonide or beclometasone at a 1:2 (i.e.,
equipotent) dose ratio. The odds ratio for patients on fluti-
casone experiencing an OCS exacerbation, compared to
those on budesonide or beclometasone was 0.74 (95% CI:
0.53, 1.03). The corresponding odds ratios for withdrawal
due to exacerbation and withdrawal due to lack of efficacy
were 0.77 (0.54, 1.10) and 0.59 (0.33, 1.07), respectively.
Thus the odds of each event were between 26% to 41%
lower with fluticasone versus budesonide/beclometasone
and in all three cases approached significance suggesting a
trend in favor of fluticasone. No other similarly compre-
hensive meta-analyses are available, and sample sizes in
individual studies have to date been too small to determine
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whether the trends suggested by Adams et al.’s data are
reproducible.
Pharmacological differences between ICSs may explain
the trend in the meta-analysis by Adams et al. Fluticasone is
considerably more lipophilic than budesonide and beclome-
tasone. It therefore exhibits slower dissolution through the
aqueous airways surface fluid layer,(77,78) prolonged contact
with the airway epithelium, greater tissue binding,(79) and
glucocorticoid receptor binding affinity(80) (hence enhanced
tissue retention). Nonetheless, budesonide undergoes intra-
cellular conjugation with fatty acids(81) that, post-absorption,
might be expected to mitigate the lesser lipophilicity of the
parent compound. Thus differences in intra-pulmonary me-
tabolism between fluticasone versus budesonide and beclo-
metasone may also be implicated in any clinical differences
between these ICSs.
All are metabolized by the cytochrome P450 3A family,
with CYP 3A5 the predominant lung isoform.(82,83) Im-
portantly, the CYP 3A5 gene is polymorphic: only patients
with at least one 3A5*1 allele express large amounts of
functional protein, with approximately 45% of African
Americans,(84) 23%–40% of Asians,(84) and 5%–15% of
Caucasians (one report suggests 30%) expressing this al-
lele.(85) In these patients, metabolic differences between
different ICSs may however be very relevant, and may
contribute to observed differences in ICS efficacy. Flutica-
sone, but not budesonide or beclometasone, is an extremely
efficient inactivator of CYP 3A5, thereby inhibiting its own
pulmonary metabolism.(82) Conversely, budesonide and
beclometasone induce CYP 3A5,(86,87) which may enhance
their pulmonary degradation. Therefore, intrapulmonary
metabolism of budesonide and beclometasone may plausi-
bly contribute to corticosteroid resistance or insensitivity,
observed in approximately 30% of asthmatics.(88,89)
Turning to the comparison of LABAs, meta-analyses re-
quested by the US Food and Drug Administration revealed
that, when fixed combination fluticasone/salmeterol was
compared to fluticasone monotherapy, there was no differ-
ence in the occurrence of asthma-related hospitalizations
(OR: 1.01; 95% CI: 0.60, 1.69),(90) whereas a 32% reduction
in the odds of asthma-related hospitalization was seen when
formoterol plus budesonide (as either a free or fixed com-
bination) was compared to budesonide monotherapy (OR:
0.68; 95% CI: 0.47, 0.99).(91)
Mechanistic studies may explain the apparent difference
in protection from exacerbations afforded by formoterol and
salmeterol. Levels of pro-inflammatory cytokines, including
IL-1b and TNFa, are increased in the airways of asthmat-
ics,(92,93) and impair the smooth muscle relaxant effects of
LABAs.(94,95) However, cytokines reduce the smooth muscle
relaxation induced by salmeterol to a significantly greater
extent (40%) than that induced by formoterol (16%).(96)
Furthermore, corticosteroid administration completely re-
verses the cytokine-induced inhibition of formoterol effect,
but has no effect on the inhibition of salmeterol effect.(96)
These differential effects may result from differences in
LABA molecular structure leading to different conforma-
tional states of the activated b2-adrenoceptor, hence dif-
ferential activation of stimulatory and inhibitory G proteins
(Gs and Gi, respectively).(96) It is plausible that salmeterol
binding to the b2-adrenoceptor activates Gi to a greater
extent than formoterol, explaining both the lesser intrinsic
efficacy of salmeterol, but also the non-reversal of cytokine-
induced inhibition of salmeterol effect by corticosteroid,(96)
since the Gia subunit is corticosteroid insensitive.(97)
Clinically therefore, salmeterol may be more vulnerable
than formoterol to inhibition by pro-inflammatory cytokines,
levels of which may be further increased during asthma
exacerbations.(96)
A second potentially important difference between sal-
meterol and formoterol lies in their disposal from smooth
muscle cells, and the effect of ICSs upon this disposal. The
clearance of cationic drugs from airway smooth muscle cells
is facilitated by cationic transporters, with organic cation
transporter (OCT) 3 being the predominant species.(98)
OCT3 is inhibited by corticosteroids;(98) thus ICS may in-
hibit the disposal of cationic formoterol from smooth muscle
cells and thereby increase local tissue concentrations. This
beneficial interaction is not seen for (lipophilic) salmeterol,
as it is not a substrate for OCT3 and its disposal is not
therefore slowed by corticosteroid co-administration.(98)
Finally, cAMP production induced by formoterol is
resistant to oxidative stress, whereas that induced by sal-
meterol is not;(99) furthermore, formoterol reverses corti-
costeroid insensitivity under conditions of oxidative stress
whereas salmeterol does not.(99) It is hypothesized that
these differences are due to inhibition of PI3Kd signalling
by formoterol but not salmeterol.(99) Thus, formoterol may
confer greater clinical benefit than salmeterol under oxi-
dative stress, for example in severe asthmatics or in asth-
matic smokers.
In conclusion, a low incidence of exacerbations was seen
in two fixed dose fluticasone/formoterol studies, which was
considerably lower than in the majority of comparable
published studies involving other combinations of ICS/
LABAs. Whilst recognizing the limitations of this cross-trial
comparison, it is plausible that the low event incidence with
fluticasone/formoterol is related to each of its constituent
components exhibiting favorable characteristics compared
to other widely used drugs in their respective classes. Fur-
ther head-to-head studies comparing fluticasone/formoterol
to other ICS/LABAs are warranted to ascertain whether the
observations in this cross-trial setting can be replicated.
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